Hoggar

Quick links to important sections

Hoggar

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hoggar

Quick Facts

Property Description
Active ingredient Doxylamine succinate
Form Oral tablet / Film-coated tablet
Pharmacological class First-generation Antihistamine
Common use Temporary sleep aid
Origin Synthetic compound

Classification and Identity: What Type of Medicine is Hoggar?

Hoggar is a pharmaceutical preparation available over-the-counter and is classified as a First-generation antihistamine, whose primary functional role is that of a temporary sleep aid. The medication is defined by its active ingredient, Doxylamine, a synthetic compound belonging to the Ethanolamine-derivative antihistamine group. This particular classification is important because these older antihistamines are chemically distinct from newer forms, having the ability to cross the blood-brain barrier to produce central nervous system effects.

Composition and Form: What is the Active Ingredient in Hoggar?

The core active component in this preparation is Doxylamine succinate, which is used as a single-ingredient product and is formulated for oral intake. It is commonly supplied as an oral tablet or a film-coated tablet. Doxylamine is classified as a powerful H1 receptor antagonist, characterized by its efficacy in inducing drowsiness and facilitating sleep. The final tablet form combines the active compound with standard pharmaceutical excipients necessary for stability and structure.

General Purpose: What is the Function of this Sedating Antihistamine?

The primary function of this medication is derived from its role as an H1 receptor antagonist, which leads directly to its sedative properties and subsequent hypnotic effect. By interfering with specific neurological signals that promote wakefulness, this sedating antihistamine effectively reduces alertness and promotes drowsiness. This pharmacological action relates to its role as a resource for adults experiencing insomnia or acute sleep disorders, such as difficulty falling asleep due to temporary stress or jet lag.

Regulatory References

  1. Doxylamine - StatPearls - NCBI Bookshelf (NIH)

What side effects are possible with Hoggar?

Possible side effects and safety information

Adverse reaction scope

The medicine's safety profile is formally documented by regulatory authorities, with adverse reactions generally classified as stemming from CNS depression and anticholinergic effects. The primary and most frequently reported reaction is the onset of drowsiness.

  • Frequency Classification: Somnolence (drowsiness) is officially classified as a Very Common adverse reaction, meaning it may affect more than 1 in 10 individuals. Dizziness is documented as a Common effect [MHRA, FDA Label].
  • System-Organ Classes Involved: Adverse reactions have been reported across multiple systems, including Nervous System Disorders (headache, disorientation), Gastrointestinal Disorders (constipation, dry mouth), Eye Disorders (blurred vision), and Cardiac Disorders (palpitations, tachycardia) [FDA Label, Medsafe].
  • Serious Adverse Reactions: The regulatory framework documents that overdose can lead to severe anticholinergic toxicity, which may involve seizures, profound central nervous system depression, and potentially fatal complications such as rhabdomyolysis (muscle breakdown) and cardiorespiratory arrest [Medsafe]. Severe allergic reactions (hypersensitivity) are also documented.

Population-Specific Safety Considerations and Restrictions

Official labeling defines specific safety constraints for certain populations and co-administered substances:

  • Older Adults (Geriatric Population): This population is documented to have an increased susceptibility to anticholinergic adverse effects, including confusion and urinary retention [NIH/MedlinePlus].
  • Pediatric Population: Use as a sleep aid is contraindicated in children under 12 years of age, as misuse is associated with a risk of serious adverse effects [DailyMed Label].
  • Safety Constraints: The medicine is contraindicated with Monoamine Oxidase Inhibitors (MAOIs) due to the potential for intensified central anticholinergic effects [FDA Label]. Additionally, concurrent use with alcohol or other CNS depressants is not recommended due to the potential for severe additive sedation [FDA Label].
  • Exposure Pattern: Users must plan for adequate sleep time, as residual somnolence may persist the morning after use [NIH/MedlinePlus].

Connection to the overall safety profile:

Official safety information structures the risk profile around the Very Common occurrence of somnolence and the potential for systemic anticholinergic actions. The explicit constraints on age, co-administered drugs, and specific pre-existing conditions formally delineate the high-risk environments and patient groups for whom the medicine is not suitable, underscoring the necessity of using the medicine strictly according to regulatory conditions.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Presentations and Severe Outcomes

Overdose with this medication is documented by regulatory authorities to present as signs of anticholinergic toxicity, including fixed and dilated pupils (mydriasis), dry mouth, tachycardia, mental confusion, and central effects such as restlessness and hallucinations.

At toxic exposures, severe outcomes are explicitly listed in regulatory labeling. These potentially fatal reactions include grand mal seizures, coma, and systemic complications such as rhabdomyolysis leading to acute renal failure. Both cardiorespiratory arrest and fatalities have been reported in overdose cases. Children are noted to be at a high risk for cardiorespiratory arrest following an overdose, and a specific toxic dose has been reported for this population. Symptoms may also be delayed depending on the tablet formulation.

Mandatory Emergency Response

Due to the documented risk of potentially fatal cardiovascular or CNS reactions, regulatory authorities mandate that immediate medical attention must be sought in the event of an overdose. Contact the Poison Help line or emergency services immediately if the affected person has collapsed, had a seizure, has trouble breathing, or can't be awakened. Treatment is described as symptomatic and supportive care, including measures such as activated charcoal and continuous monitoring of vital signs.

Therapeutic Uses of Hoggar

What Hoggar treats: Main Uses and Benefits

Hoggar (Doxylamine succinate) is a medication generally used by adults specifically for the symptomatic management of occasional sleep disorders. The application of the active ingredient includes addressing difficulty falling asleep or staying asleep. Its therapeutic application is focused on providing supportive relief when acute sleep disruption occurs.

Management of Acute Sleep-Onset and Sleep Maintenance Symptoms

This medication is applied in situations where patients experience noticeable difficulty in falling asleep or maintaining sleep throughout the night. It is used for managing symptom clusters that create noticeable interference with daily comfort, such as prolonged periods of heightened physiological activity at bedtime. The primary therapeutic benefit is to promote a state of drowsiness that may assist with the process of sleep initiation and is associated with general well-being during acute episodes. It is relevant for easing symptoms associated with conditions such as temporary emotional stress and disturbances linked to jet lag.

Support for Transient Sleep Disruption

Hoggar is considered relevant in conditions involving episodic or fluctuating symptom patterns, applied when short-term symptomatic assistance is needed. The medication offers symptomatic relief that contributes to maintaining daily routine consistency during temporary episodes of sleeplessness.

Quick Fact: Relief for Sleep Disruption
Primary Indication: Occasional, temporary insomnia
Symptom Focus: Difficulty falling asleep, trouble staying asleep
Key Benefit: Supports the process of sleep initiation and sleep maintenance

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for Hoggar (Doxylamine succinate) is strictly defined by regulatory documents, specifying who may use the medicine and under which conditions.

Eligibility Status Defined Population
Permitted Use Adults and children 12 years of age and older (for temporary sleep aid use).
Contraindicated Individuals with known hypersensitivity to the drug or concurrent use of Monoamine Oxidase Inhibitors (MAOIs).

Use is formally contraindicated in patients diagnosed with narrow-angle glaucoma and those with obstructive conditions of the digestive or urinary tract, such as stenosing peptic ulcer, pyloroduodenal obstruction, or urinary bladder-neck obstruction. The official eligibility profile is further structured by specific population restrictions:

  • Use in children under 12 years for this indication is not established and therefore not recommended.
  • Caution is advised for patients with hepatic or renal impairment due to regulatory concerns over drug metabolism and accumulation.
  • Individuals with breathing problems (like chronic bronchitis) or conditions causing difficulty urinating, such as prostatic hypertrophy, are subject to eligibility restrictions.
  • For pregnancy, consultation with a clinician is required before use, and use during lactation is not recommended due to the potential for the drug to pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation defines the interaction profile for Doxylamine succinate (Hoggar) primarily through pharmacodynamic mechanisms, focusing on additive effects on the central nervous system (CNS) and anticholinergic systems.

Interaction-Related Restrictions

Classification Interacting Substance / Category Official Regulatory Statement
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Co-administration is prohibited due to the risk of intensifying and prolonging the anticholinergic effects of Doxylamine. A 14-day separation is required between stopping MAOI therapy and starting this medication.
Not Recommended Use Alcohol (Ethanol) Concurrent use is not recommended due to the significant risk of additive CNS depression, resulting in severe drowsiness and impairment.
Use with Caution CNS Depressants (e.g., Opioids, Anxiolytics) Co-administration is not recommended, as it causes an additive effect that increases the risk of profound sedation.
Additive Effect Anticholinergic Agents Combination may enhance toxicity and worsen anticholinergic adverse effects, such as dry mouth and urinary retention.

Procedural Interaction Constraints

Taking the medication with food may delay the onset of action and reduce its absorption, leading to a regulatory recommendation to administer the dose on an empty stomach. Furthermore, the use of Doxylamine may lead to false positive results for certain substances (e.g., methadone, opiates) in specific urine drug screens (immunoassays), a constraint that may necessitate confirmatory testing.

Mechanism of Action

Hoggar contains doxylamine succinate, a first-generation histamine H1 receptor antagonist.

The molecule readily crosses the blood-brain barrier and exerts its primary action in the central nervous system (CNS) by binding reversibly to neuronal histamine H1 receptors as an inverse agonist or antagonist. This competitive blockade of H1 receptors modulates the histaminergic signaling pathway in wake-promoting circuits, particularly in the tuberomammillary nucleus.

Downstream, this reduces histamine-mediated activation of cortical and subcortical structures. The compound also exhibits secondary anticholinergic activity, functioning as an antagonist at peripheral and central muscarinic acetylcholine receptors (M1–M5), further contributing to its overall central effects. The net system-level physiological consequence is a widespread central nervous system depression, modifying the sleep-wake cycle.

Dosage and Administration Information

How Hoggar is Used: Official Administration Guidelines

Hoggar (Doxylamine succinate) is administered according to a standardized protocol to ensure proper use as a temporary sleep aid. The instructions focus strictly on dosing, timing, and administration context.


Standard Dosing and Schedule

The approved route of administration is oral. The standard dose for adults and children 12 years of age and over is 25 mg (one tablet).

Usage Parameter Instruction
Dose 25 mg (one tablet)
Frequency Once daily (qHS)
Maximum Dose 25 mg in a 24-hour period
Age Restriction Do not use in children under 12 years of age

Timing and Duration of Use

Administration Timing: The dose is typically taken approximately 30 minutes before going to bed. The medicine is taken at bedtime and is intended for use when enough time is available for a full night's sleep, generally defined as 7 to 8 hours.

Course Duration: This medication is intended for short-term use for occasional sleep difficulty. Standard practice involves discontinuing use and seeking clinical assessment if sleeplessness persists continuously for more than two weeks.

These guidelines define the standardized, time-constrained usage protocol for the medicine, focusing on a single nighttime dose for temporary application.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Research has investigated the use of doxylamine succinate (the active ingredient in Hoggar) for transient sleep disturbances and its potential relationship with patient recovery and symptoms.


Research Focus and Core Studies

Research has investigated the biological properties of the drug, noting its classification as a first-generation H1-receptor antagonist with sedative effects. The primary trials assessed potential changes in symptoms and time to recovery for occasional sleeplessness.

  • Sleep Onset and Duration: Multiple placebo-controlled studies have evaluated the relationship between doxylamine succinate (typically 25 mg) and subjective patient ratings of sleep latency (time to fall asleep), nocturnal awakenings, and total sleep duration. Some studies indicate a statistically significant difference compared to placebo in promoting sleep induction and increasing total sleep time over short-term use.
  • Population Focus: Studies primarily focused on adult patients with chronic intermittent sleep impairment or transient insomnia. Research noted a decreased clearance and prolonged half-life of doxylamine in elderly men compared to younger men.
  • Other Uses: In combination with pyridoxine (Vitamin B6), doxylamine has been studied and authorized for the treatment of nausea and vomiting during pregnancy.

Special Populations and Adjunctive Use

Pediatric Populations

Evidence remains limited on the use of doxylamine succinate as a sleep aid in pediatric populations. While some antihistamines may be prescribed for children for selected conditions, clinical data specifically supporting doxylamine's use for primary insomnia in younger children is sparse.

Alternative Formulations

Research explored alternative drug delivery methods, such as intranasal formulations, designed to deliver a potentially more rapid onset of effect. However, a Phase 1 study in adults with sleep impairment did not find that the intranasal spray increased the systemic bioavailability of doxylamine succinate compared with the standard oral tablet.

Frequently Asked Questions (FAQ)

Common questions about Hoggar (FAQ)


Q: How quickly does Hoggar typically start to work?

Regulatory guidelines describe administration as taking the dose approximately 30 minutes before going to bed. Pharmacokinetic data from studies indicate that the active ingredient reaches its highest level in the bloodstream, known as peak plasma concentration, typically within two to three hours after the dose is taken by mouth.


Q: How long are the effects of Hoggar expected to last?

Official administration instructions specify the condition of use, stating the medicine is to be administered only when 7 to 8 hours are available for sleep. The rate at which the active ingredient is eliminated from the body is measured by its half-life, which is approximately 10 hours in healthy adults.


Q: Is Hoggar generally considered suitable for older adults (seniors)?

Official information advises caution for use in older adults. This population may have an increased susceptibility to certain side effects known as anticholinergic effects, such as confusion and difficulty urinating. Studies also show that the active ingredient may stay in the body for a longer period in elderly men due to slower clearance.


Q: What types of heart conditions are listed as cautions for Hoggar use?

Official safety information and warnings advise caution for cardiovascular disorders. This is because the medicine has the potential to cause anticholinergic side effects that may infrequently include heart-related issues such as palpitations (an unusual awareness of the heartbeat) or tachycardia (an abnormally fast heart rate).


Q: What happens if you take Hoggar for several nights in a row?

Hoggar is officially indicated for short-term use to treat occasional sleep difficulty. Clinical guidelines suggest that if the medicine is used for several nights continuously, pharmacological tolerance may begin to develop, meaning the effects might become less noticeable. This is why regulatory bodies limit the duration of use.


Q: Why does the label recommend not exceeding the suggested use duration?

The regulatory label specifies that use should be discontinued and professional advice sought if sleeplessness persists continuously for more than two weeks. This is because persistent insomnia may be an important symptom of a serious, underlying medical condition that requires proper diagnosis and treatment beyond an over-the-counter sleep aid.


Q: Is there an official list of all inactive ingredients in Hoggar?

Yes, official drug labels, such as those provided by the FDA, are required to include a complete list of all ingredients. This list covers the active component and all 'excipients,' which are the inactive substances necessary for the final tablet formulation, such as fillers, binders, and coloring agents.


Q: Why is Hoggar sometimes referred to as a 'non-prescription' option?

Hoggar is classified as an over-the-counter (OTC) medicine. This classification means regulatory bodies have determined that its active ingredient, when used strictly as directed on the label, is safe and effective enough for sale to the public without needing a doctor’s prescription.


Q: Can Hoggar be taken if I am already taking blood pressure medication?

The official warnings state that consultation with a doctor or pharmacist is advised before using this medicine if you are taking any other prescription or non-prescription drugs. This is advised because potential interactions, including those with certain blood pressure medications like beta-blockers, can occur.


Q: Are there any known issues with drinking coffee while using Hoggar?

Official cautions primarily focus on avoiding substances that cause additive CNS depression, such as alcohol. The category of CNS stimulants, which includes caffeine found in coffee, is generally noted for potential counter-effects to the sedative action. Stimulants are not specifically addressed in the regulatory warnings.


Q: Do regulatory documents mention a risk of dependence with Hoggar?

Official product information for the active ingredient often describes the medicine as a 'non-habit forming' antihistamine. This classification indicates that the active ingredient is not associated with the same risks of dependence as some other types of medications used for sleep.


Q: Is Hoggar known to interact with herbal supplements?

The official patient information includes a general cautionary statement that consultation with a healthcare professional is advised before taking any other drugs or supplements. Interactions are possible with a wide range of products, including certain herbal supplements, that might enhance side effects or interfere with how the medicine works.


Q: Is there scientific research available about Hoggar's use in younger adults?

Clinical studies supporting the use of this medicine primarily focus on the broad adult population who experience transient insomnia. The safety and effectiveness of the medicine have not been established in children under 12 years of age, and specific data distinguishing 'younger' from 'older' adults for this indication are limited.


Q: What does 'contraindicated' mean in the context of who should not use Hoggar?

The term 'contraindicated' is used in official documentation to describe a specific condition or factor that absolutely forbids the use of the medicine. It signifies that using the medication in this circumstance is likely to cause harm or worsen the patient's existing medical condition.


Q: Is it possible to develop a tolerance to Hoggar over time?

Yes, regulatory documentation and clinical guidelines indicate that the body can develop tolerance to the sedative effects of the active ingredient with continued, repeated use. This is why the medicine is intended and labeled exclusively for short-term, occasional sleep treatment.


Q: Why do some users report vivid dreams when using Hoggar?

Official safety documentation notes that the medicine’s effects on the central nervous system can rarely include disturbances like nightmares and hallucinations. While vivid dreams are not listed as a common side effect, these reports are consistent with the known adverse reaction profile of the active ingredient.


Q: Are there specific instructions for what to do if a dose is missed?

Official dosage instructions state that the medicine is only administered once daily at bedtime. If a dose is missed, the regulatory instruction is to skip the missed dose and resume the regular schedule the next evening. This is intended to prevent double dosing.


Q: Does Hoggar interact with common pain relievers like ibuprofen?

The official warnings state that consultation with a doctor or pharmacist is advised before using this medication with any other drugs. While common pain relievers are not explicitly listed, this consultation ensures there are no potential interactions that could increase the risk of side effects.


Q: Is Hoggar known to cause any long-term effects?

This medication is not recommended for long-term use. Due to its classification and properties, prolonged use, particularly in older adults, has been examined in some studies regarding potential long-term adverse effects like cognitive impairment.


Q: Do studies exist that compare different doses of Hoggar?

Yes, pharmacokinetic studies have been performed on the active ingredient to understand how it behaves in the body. These studies have confirmed that the action of the active ingredient is proportional to the dose administered within the typical therapeutic range.


Q: What happens if I forget whether I have taken Hoggar or not?

Official instructions strictly caution against double dosing due to the medicine's sedative effect. If uncertainty exists about whether a dose was administered, the guidance is to skip the dose and wait until the following night to resume the regular schedule.


Q: Is Hoggar described as non-habit forming in official documents?

Yes, some official product information and marketing claims refer to the active ingredient as a 'non-habit forming' antihistamine. This is based on regulatory assessment of the medicine's potential for abuse or dependence.


Q: What are the general rules for stopping Hoggar use?

For occasional, transient use, official instructions state the medicine can generally be discontinued without a gradual reduction (taper). However, regulatory limits require that if the medicine has been used continuously for the two-week maximum duration, consultation with a healthcare professional is advised before making further decisions.


Q: Can Hoggar be used alongside dietary supplements like Melatonin?

The official patient warnings state that consultation with a doctor or pharmacist is advised before combining Hoggar with any other drugs or supplements. Co-administration of this medicine with supplements that also cause drowsiness, such as melatonin, may increase the risk of excessive sedation and other side effects.


Q: Are there reports of paradoxical reactions (opposite effect) to Hoggar?

Yes, official safety documentation notes that the active ingredient may rarely cause central nervous system stimulation rather than sedation. This is referred to as a paradoxical reaction and has been reported as causing symptoms like insomnia, nervousness, and irritability, particularly in children.

How should Hoggar be stored and disposed of?

Storage and Protection Requirements

Official regulatory documents require that Hoggar (doxylamine succinate) be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be maintained in its original container, which should be kept tightly closed and away from excessive heat and moisture to preserve stability.

Child-Safety Mandate

It is a mandatory safety requirement that this medicine be kept strictly out of the sight and reach of children at all times. This rule is in place due to the serious risks associated with accidental pediatric ingestion.

Official Disposal Rules

Unused or expired medication must be disposed of according to local regulations. The preferred method is through a drug take-back program. As an alternative, the medicine should be removed from its container, mixed with an undesirable substance like coffee grounds or cat litter, sealed in a bag, and then placed in the household trash. The original container's labels must be defaced to protect personal information.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hoggar found in:

A-Z Index: